ライフサイエンスコーパス: portal pressure

1 nsation in cirrhosis, possibly by increasing portal pressure.

2 is extent (hydroxyproline concentration) and portal pressure.

3 nic blood flow, portohepatic resistance, and portal pressure.

4 clude bleeding, thrombosis, and elevation of portal pressure.

5 horylation and NO production, and normalized portal pressure.

6 duced the elevated mesenteric blood flow and portal pressure.

7 ficantly reduced intrahepatic resistance and portal pressure.

8 -L-arginine reduced NO release and increased portal pressure.

9 endogenous endothelial-derived NO modulates portal pressure.

10 ute to increased intrahepatic resistance and portal pressure.

11 on by IFX was associated with a reduction in portal pressure.

12 mol/L) caused a rapid and pronounced rise in portal pressure.

13 Both TIPS and HGPCS reduced portal pressure.

14 , animals with hepatic fibrosis had a higher portal pressure (13.0 +/- 3.6 vs. 3.7 +/- 1.4 mm Hg, P <

15 Reduction of elevated portal pressure after 80% PH by terlipressin was associa

16 trahepatic portosystemic shunts (TIPS) lower portal pressure and have been used in the treatment of r

17 s blood flow (PVBF) has been shown to reduce portal pressure and intrahepatic vascular resistance and

18 etic resonance elastography, correlated with portal pressure and preceded fibrosis in our model.

19 nselective beta-adrenergic blockers decrease portal pressure and prevent variceal hemorrhage.

20 rial and portal blood flow, without changing portal pressure and renal blood flow.

21 acute and chronic JWH-015 treatment reduced portal pressure and superior mesenteric arterial blood f

22 Nonselective beta blockers (NSBBs) reduce portal pressure and the risk for variceal hemorrhage in

23 ative causes of EAD after LDLT are excessive portal pressure and/or flow.

24 define prospectively the effects of TIPS on portal pressures and flow, variceal resolution, and hepa

25 Each procedure significantly reduced portal pressures and portasystemic pressure gradients.

26 Liver fibrosis, portal pressure, and hepatic tumor burden in BALB/c.Mdr2

27 Mean arterial pressure, portal pressure, and SMA blood flow were measured by cat

28 tance was calculated from arterial pressure, portal pressure, and SMA flow.

29 ion were attenuated based on immunostaining, portal pressure, and spleen/body weight ratio.

30 rhotic nodules correlated independently with portal pressure (as determined by the hepatic venous pre

31 Alcoholic hepatitis patients have higher portal pressures associated with increased ADMA, which m

32 nsated cirrhosis, exercise acutely increases portal pressure, but in the longer term it has been prov

33 R downstream signaling pathway and decreased portal pressure by lowering total IHVR without deleterio

34 Mean arterial pressure, portal pressure, cardiac output, total peripheral resist

35 rtension (PHT) is characterized by increased portal pressure caused in part by a reduction in mesente

36 nchnic blood flow contribute to the elevated portal pressure characteristic of PHT.

37 significantly reduced portal blood flow and portal pressure compared to vehicle (13.6 +/- 5.7 versus

38 Additionally, an increase in portal pressure concomitant with the blockade of NO rele

39 rahepatic portasystemic stent shunts reduced portal pressures from 32 +/- 7.5 mmHg (standard deviatio

40 BACKGROUND & AIMS: A reduction in portal pressure gradient (PPG) to <12 mm Hg after placem

41 n was improved by TIPS in all patients (mean portal pressure gradient before TIPS, 20.2 +/- 4.6 vs. 6

42 The portal pressure gradient was determined based on HVPG at

43 Within the first 5 days, the portal-pressure gradient increased significantly in pati

44 l flow in animals with hepatic fibrosis, the portal pressure greatly reduced (13.0 +/- 3.6 to 2.5 +/-

45 he lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and m

46 Modulation lowered portal pressure in 68% of subjects with inconsistent eff

47 IRL 1620 (an ET(B) agonist) increased portal pressure in a dose-dependent manner, and the incr

48 Terutroban reduced portal pressure in both models without producing signifi

49 -receptor blockade with terutroban decreases portal pressure in cirrhosis.

50 c oxide (NO) donor, has been shown to reduce portal pressure in cirrhotic patients.

51 derate exercise were safe and reduced BW and portal pressure in overweight/obese patients with cirrho

52 ced a selective and significant reduction in portal pressure in pathologically distinct PHT models, t

53 Statins decrease portal pressure in patients with cirrhosis and increase

54 d ETB receptor antagonist, bosentan, reduced portal pressure in portal hypertensive animals, consiste

55 tion of Akt and production of NO and reduced portal pressure in portal hypertensive rats.

56 the hyperdynamic circulation, and decreases portal pressure in PVL-operated rats.

57 wn mediators of stellate cell contraction on portal pressure in rat livers after carbon tetrachloride

58 blocker, decreases hepatic vascular tone and portal pressure in rats with cirrhosis due to carbon tet

59 s contributes to the maintenance of elevated portal pressure in these animals.

60 s with cirrhosis, and if weight loss reduces portal pressure in this setting, is unknown.

61 reatment of portal hypertension would reduce portal pressure, increase renal blood flow, and produce

62 Portal pressure increased from about 3 to 10.5 cm H2O up

63 During volume expansion, similar portal pressure increases were observed in CIH and HC ra

64 MasR blockade reduced portal pressure, indicating that activation of this rece

65 esized that vWF-Ag levels may correlate with portal pressure, measured by hepatic venous pressure gra

66 The effects of sedatives on portal pressure measurements have not yet been defined.

67 should be assessed by venography and direct portal pressure measurements until a more reliable and p

68 Portal pressure measurements were elevated in 2 patients

69 Reduction of elevated portal pressure post-PH by the use of terlipressin impro

70 05) and significantly attenuated the rise in portal pressure (PP) (12.7 +/- 0.8 vs. 15.2 +/- 0.5 mm H

71 erformed hemodynamic measurements, including portal pressure (PP) and portosystemic shunts (PSS), and

72 RVXB significantly decreased portal pressure (PP) in both models of cirrhosis without

73 stomach lumen increases splanchnic flow and portal pressure (PP) in portal-hypertensive rats.

74 tion have shown their usefulness in reducing portal pressure (PP) in this condition.

75 Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifi

76 reased systemic vascular resistance, reduced portal pressure (PP), superior mesenteric artery flow, m

77 IPS) (8 mm; n = 90), or medical reduction of portal pressure (propranolol and isosorbide-5-mononitrat

78 rdynamic circulation and significantly lower portal pressure reduction after acute beta-blockade than

79 examine splanchnic vascular hemodynamics and portal pressure response.

80 Atorvastatin decreased portal pressure, shunt flow and angiogenesis in cirrhosi

81 l infection results in a further increase in portal pressure through the induction of endothelin and

82 vascular resistance and significantly lower portal pressure, TNF plasma levels, and 24-hour urinary

83 e activity, indocyanine green secretion, and portal pressure values were determined at major time poi

84 Mean portal pressure was dropped from 33.08 +/- 1.38 mmHg pre

85 Portal pressure was measured to test whether Nogo-B gene

86 rols (P = 0.03), whereas such an increase in portal pressure was not observed in NGB KO mice (P = NS)

87 Four weeks after BDL, portal pressure was significantly increased in WT mice b

88 Necroinflammation, fibrosis, and portal pressure were either histologically scored or bio

89 potent stellate cell contractile agonist) on portal pressure were greater in cirrhotic than normal li

90 Transient elevations of the portal pressure were observed during cell infusion.

91 Hepatic fibrosis and portal pressure were significantly increased after pIVCL

92 ery blood flow, and systemic, pulmonary, and portal pressures were measured.

93 vers, which correlated with the reduction in portal pressure when compared with simple cold storage (

94 (ETB) receptor agonist, had minor effects on portal pressure when perfused into normal livers at conc